TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24851544

Group type: EXPERIMENTAL
Intervention: Standard intensive rehabilitation combined with air (FiO2 = 21%) pressurized to 1.3 atm abs (n = 40)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standard intensive rehabilitation combined with 100% oxygen pressurized at 1.5 atm abs (n = 32)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standard intensive rehabilitation combined with 100% oxygen pressurized at 1.75 atm abs (n = 58)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard intensive rehabilitation only (control group n = 20)
Number of subjects: 150
Study: 22994867

Group type: EXPERIMENTAL
Intervention: Psychoacoustic Advanced Combination Encoder (PACE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Advance Combination Encoder (ACE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Original stimuli
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simulated stimuli (ACE and PACE)
Number of subjects: 20
Study: 19888030

Group type: EXPERIMENTAL
Intervention: Membrane sweeping
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control (weekly vaginal assessment for Bishop score)
Number of subjects: 213
Study: 17513664

Group type: EXPERIMENTAL
Intervention: 1.5 mg hyperbaric bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 6.0 mg hyperbaric bupivacaine
Number of subjects: 80
Study: 15159466

Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 to 30 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11591616

Group type: EXPERIMENTAL
Intervention: Chagas' heart disease patients (CH) during hypoxia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matched control subjects (C) during hypoxia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chagas' heart disease patients (CH) during hypercapnia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matched control subjects (C) during hypercapnia
Number of subjects: 12
Study: 9542516

Group type: EXPERIMENTAL
Intervention: Screen-detected group (FOB screening)
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Non-responders (no screening)
Number of subjects: 150000

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 150000
Study: 8300690

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Debridement
Number of subjects: 80
Study: 3182116

Group type: EXPERIMENTAL
Intervention: Thienamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 0
Study: 30467829

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fresh frozen plasma
Number of subjects: 20
Study: 27585447

Group type: EXPERIMENTAL
Intervention: 3-month guided hiking programme (2-3 times a week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Activities of daily living (control group)
Number of subjects: 48
Study: 26424091

Group type: EXPERIMENTAL
Intervention: E-cigarettes with 1.6% and 2.4% nicotine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional tobacco cigarette
Number of subjects: 24
Study: 23382519

Group type: EXPERIMENTAL
Intervention: Low frequency (LF) SPG stimulation for 3 minutes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High frequency (HF) SPG stimulation for treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: High frequency (HF) SPG stimulation for 3 minutes
Number of subjects: 6
Study: 22142327

Group type: EXPERIMENTAL
Intervention: Short Message Service with Interactive Voice Response (SMS-IVR) intervention, including training of professionals (medical oncologists, nurses, and general practitioners)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (standard care without SMS-IVR)
Number of subjects: 0
Study: 19159726

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: VATS
Number of subjects: 36
Study: 17573989

Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine gastrointestinal therapeutic system
Number of subjects: 7665
Study: 15118469

Group type: EXPERIMENTAL
Intervention: Endoscopic cyclophotocoagulation (ECP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ahmed drainage implant
Number of subjects: 68
Study: 12419034

Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 72
Study: 10030556

Group type: EXPERIMENTAL
Intervention: N2/CO2 gas mixture exposure for 1 hour
Number of subjects: 35
Study: 7553416

Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Number of subjects: 77

Group type: COMPARATOR
Intervention: clindamycin plus gentamicin
Number of subjects: 77
Study: 1979522

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) 50 mg/kg once a week in a 3-hour infusion with 1 g oral probenecid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6106322

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Somatostatin and Cimetidine
Number of subjects: 20
Study: 31797844

Group type: EXPERIMENTAL
Intervention: Collagen dressing
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Light-cure dressing
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Non-eugenol-based dressing
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 45
Study: 27835050

Group type: EXPERIMENTAL
Intervention: Moderate dose of Chromium Picolinate (600 mcg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin AUC (all groups)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin Sensitivity Index (ISI) (all groups)
Number of subjects: 24
Study: 25549827

Group type: EXPERIMENTAL
Intervention: Washing and disinfection of toys and linen every two weeks for three months
Number of subjects: 587

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 587
Study: 23864641

Group type: EXPERIMENTAL
Intervention: 5% CO2 inhalation during LBNP
Number of subjects: 11

Group type: COMPARATOR
Intervention: SHAM (room air) during LBNP
Number of subjects: 11
Study: 21118266

Group type: EXPERIMENTAL
Intervention: Transfusion of intra-operative autologous whole blood
Number of subjects: 20
Study: 19179490

Group type: EXPERIMENTAL
Intervention: Vitamin D (100,000 IU of cholecalciferol)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 365
Study: 17298973

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study: 15945548

Group type: EXPERIMENTAL
Intervention: spiramycin + lidase
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: lincomycin + lidase
Number of subjects: 19

Group type: COMPARATOR
Intervention: co‐trimoxazole, metronidazole
Number of subjects: 19
Study: 11149999

Group type: EXPERIMENTAL
Intervention: Icatibant (200 microg per nostril)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 11
Study: 9305478

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 250 mg q.d.s (group B)
Number of subjects: 72
Study: 8103372

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.015 micrograms.kg/min)
Number of subjects: 26
Study: 3095522

Group type: EXPERIMENTAL
Intervention: High aluminum load from experimental high calcium- and phosphorus-containing PN solution (306 +/- 26 micrograms/L) for up to 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lower aluminum load from standard Ca-P solutions (144 +/- 16 micrograms/L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 20
Study: 29517580

Group type: EXPERIMENTAL
Intervention: Group A (topical prostaglandins)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Group B (topical beta blockers and carbonic anhydrase inhibitors)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Control group (no intraocular pressure-lowering medications)
Number of subjects: 904
Study: 28288051

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 26153365

Group type: EXPERIMENTAL
Intervention: Bortezomib-thalidomide-dexamethasone (VTD)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) negative patients
Number of subjects: 98
Study: 22746337

Group type: EXPERIMENTAL
Intervention: Yohimbine 5 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 38
Study: 21480974

Group type: EXPERIMENTAL
Intervention: Intensive glucose management
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional glucose management
Number of subjects: 300
Study: 19726643

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 22
Study: 17566172

Group type: EXPERIMENTAL
Intervention: Aromatic oils for massage
Number of subjects: 31
Study: 15195048

Group type: EXPERIMENTAL
Intervention: Oral spray lubricant applied before bedtime
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nasal strip designed to maintain nasal valve patency
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Head-positioning pillow
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 40
Study: 11727508

Group type: EXPERIMENTAL
Intervention: Novel erythropoiesis stimulating protein (NESP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rhuEPO)
Number of subjects: 0
Study: 9012705

Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of acenocoumarol (AW)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gradual withdrawal of acenocoumarol (GW)
Number of subjects: 20
Study: 8254783

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg at night for 6 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 21
Study: 3303785

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional injection therapy (CIT)
Number of subjects: 54
Study: 2178389

Group type: EXPERIMENTAL
Intervention: Acorns (25 g carbohydrate portion)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Corn (25 g carbohydrate portion)
Number of subjects: 8
Study: 1026423

Group type: EXPERIMENTAL
Intervention: Fish protein concentrate (FPC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cow-milk protein concentrate (Casilan)
Number of subjects: 72
Study: 31650286

Group type: EXPERIMENTAL
Intervention: Real intermittent theta burst stimulation (iTBS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS)
Number of subjects: 10
Study: 27704683

Group type: EXPERIMENTAL
Intervention: Porous titanium granule (PTG) with rotary titanium brush and platelet rich fibrin (PRF) membrane
Number of subjects: 22

Group type: COMPARATOR
Intervention: Xenograft bone substitute with collagen membrane and PRF membrane
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PTG
Number of subjects: 22
Study: 26024575

Group type: EXPERIMENTAL
Intervention: Lycopene in capsule
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tomato paste
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 23121338

Group type: EXPERIMENTAL
Intervention: Hybrid therapy: pantoprazole 40 mg/b.i.d. and amoxicillin 1 g/b.i.d. for 14 days plus 500 mg clarithromycin and 500 mg tinidazole, both twice daily for the last 7 days
Number of subjects: 420

Group type: COMPARATOR
Intervention: Sequential therapy: 40 mg pantoprazole/b.i.d. for 10 days and 1 g amoxicillin/b.i.d. for the first 5 days, followed by 500 mg clarithromycin/b.i.d. and 500 mg tinidazole/b.i.d. for the last 5 days
Number of subjects: 420
Study: 21817932

Group type: COMPARATOR
Intervention: CIS map for 4 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: FSP map for 4 weeks
Number of subjects: 31
Study: 19094067

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (4.8 pmol/kg per min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 8
Study: 17409891

Group type: EXPERIMENTAL
Intervention: Radiation plus chemotherapy
Number of subjects: 157

Group type: COMPARATOR
Intervention: Radiation
Number of subjects: 157
Study: 14872448

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study: 11160760

Group type: EXPERIMENTAL
Intervention: 30 mg of memantine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9283163

Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Morphine 6 mg
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control (no epidural morphine)
Number of subjects: 421
Study: 7509261

Group type: EXPERIMENTAL
Intervention: Standard dose of urtica/pygeum preparation (300 mg of Urtica dioica root extract combined with 25 mg of Pygeum africanum bark extract)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Half the standard dose of urtica/pygeum preparation
Number of subjects: 134
Study: 3080461

Group type: EXPERIMENTAL
Intervention: Isocal supplemented with NaCl to give 2 g Na/day (Diet B)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Unsupplemented Isocal providing 1 g Na/day (Diet C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mixed foods (3-6 g Na/day) orally before gastrostomy (Diet A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Change from Diet C to Diet B
Number of subjects: 15
Study: 29088015

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Endurance exercise
Number of subjects: 11
Study: 28528561

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 26418303

Group type: EXPERIMENTAL
Intervention: Dialyser-based autotransfusion system
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cell saver system
Number of subjects: 104
Study: 22462496

Group type: EXPERIMENTAL
Intervention: Bio-Oss collagen (augmented) after 4 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bio-Oss collagen (augmented) after 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-augmented (ungrafted) after 4 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-augmented (ungrafted) after 12 weeks
Number of subjects: 33
Study: 21962092

Group type: EXPERIMENTAL
Intervention: Flunisolide HFA (2 puffs twice daily, 85 μg/puff)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Flunisolide HFA
Number of subjects: 218
Study: 18544984

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 0
Study: 16327016

Group type: EXPERIMENTAL
Intervention: ET(A)-receptor antagonist (BQ-123)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12218779

Group type: EXPERIMENTAL
Intervention: Freshly expressed juice of Echinacea purpurea herbs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 40
Study: 9857663

Group type: EXPERIMENTAL
Intervention: Urokinase plasminogen activator (u-PA) concentration and activity in plasma
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urokinase plasminogen activator (u-PA) concentration and activity in patients with IIIb stage of cancer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy adults (control group)
Number of subjects: 40
Study: 7824708

Group type: EXPERIMENTAL
Intervention: Transluminal angioplasty coupled with thrombectomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Surgical revision coupled with thrombectomy
Number of subjects: 48
Study: 2218148

Group type: EXPERIMENTAL
Intervention: Supervised training during a postgraduate course in obstetrics and gynaecology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (senior obstetrician)
Number of subjects: 0
Study: 692299

Group type: EXPERIMENTAL
Intervention: 5 sec rest period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10 sec rest period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 20 sec rest period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 40 sec rest period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 80 sec rest period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 160 sec rest period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 320 sec rest period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 640 sec rest period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1280 sec rest period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2560 sec rest period
Number of subjects: 22
Study: 31085788

Group type: EXPERIMENTAL
Intervention: Amphotericin B liposomal gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paromomycin sulfate liposomal gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daylight option of photodynamic therapy
Number of subjects: 0
Study: 30396624

Group type: EXPERIMENTAL
Intervention: Mental Practice (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive training (control group)
Number of subjects: 0
Study: 27128820

Group type: EXPERIMENTAL
Intervention: 70% ethanol locks
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) evaluation
Number of subjects: 305
Study: 24561769

Group type: EXPERIMENTAL
Intervention: Suplatast tosilate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Mequitazine
Number of subjects: 27
Study: 22241289

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with fast track care (LFT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with standard care (LS)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Open surgery with fast track care (OFT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Open surgery with standard care (OS)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 79
Study: 21143869

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided treatment
Number of subjects: 800

Group type: COMPARATOR
Intervention: Standard group (physician's assessment)
Number of subjects: 800
Study: 17106066

Group type: EXPERIMENTAL
Intervention: HIV+RTV (n=12)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HIV+no PI (n=10)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (n=10)
Number of subjects: 32
Study: 16297052

Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy (TACRO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tacrolimus plus steroids (TACRO + ST)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy (real-TACRO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tacrolimus plus steroids (real-TACRO + ST)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: real-TACRO
Number of subjects: 60

Group type: COMPARATOR
Intervention: real-TACRO + ST
Number of subjects: 60
Study: 12139288

Group type: EXPERIMENTAL
Intervention: Anatomic approach (n = 31)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Electrogram mapping approach (n = 32)
Number of subjects: 63
Study: 9569054

Group type: COMPARATOR
Intervention: FEP regimen (epirubicin 35 mg/m², etoposide 120 mg/m², cisplatin 45 mg/m²)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: FEP regimen plus low-dose GM-CSF (150 microg/day on days 5-14)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (FEP regimen)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: GM-CSF group (FEP regimen plus GM-CSF)
Number of subjects: 62
Study: 8547554

Group type: EXPERIMENTAL
Intervention: Epidural hydromorphone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine
Number of subjects: 20
Study: 2146272

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 25
Study: 285045

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy regimen A
Number of subjects: 157

Group type: COMPARATOR
Intervention: Maintenance chemotherapy regimen B
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Protocol 7601
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Protocol 7602
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Protocol 7603
Number of subjects: 157
Study: 31312931

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (CBDCA/PTX)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Oral uracil-tegafur (UFT)
Number of subjects: 402
Study: 28403457

Group type: EXPERIMENTAL
Intervention: MiQuit intervention (tailored text messaging cessation support)
Number of subjects: 15
Study: 25753162

Group type: EXPERIMENTAL
Intervention: Fully biodegradable nasal packing Nasopore®
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control packing (traditional nasal packing)
Number of subjects: 83
Study: 24876196

Group type: EXPERIMENTAL
Intervention: DR continuous positive airway pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: DR ETI with early surfactant administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxygen saturation targets of 85‐89%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen saturation targets of 91‐95%
Number of subjects: 0